Induced pluripotent stem cells (iPSCs) have deeply affected biomedical research by offering a renewable source of patient‑specific cells. Their ability to differentiate into virtually any cell type makes them a cornerstone of regenerative medicine, disease modeling, and drug discovery. Over the past decade, the field has accelerated, with researchers worldwide exploring how iPSCs can be...
Over the past decade, induced pluripotent stem cells (iPSCs) have reshaped the landscape of biological research. What began as a breakthrough in cellular reprogramming has evolved into a powerful platform for exploring human development, modeling disease mechanisms, and dissecting the genetic foundations of cellular behavior. Today, the combination of precise genome editing and directed...
Glycans, also known as carbohydrates or polysaccharides, are fundamental constituents of all cellular life. They play essential roles in various biological processes, including cell-to-cell communication, immune response, and disease progression, among others. Accurate glycan purification, glycan identification, and anti-glycan antibody assays are crucial in advancing our understanding of...
Anti-glycan antibodies represent one of the most promising yet challenging frontiers in biotechnology. Their ability to decode the "sugar language" of cells opens doors to diagnostics, therapeutics, and vaccine design—but the complexity of glycans demands advanced technologies and collaborative innovation.
The Challenge of Glycan Complexity
Unlike DNA or proteins, glycans...
For patients living with neurological disorders—stroke, traumatic brain injury, or spinal cord damage—the wait for effective therapies can feel endless. The reality is that developing a new drug can take more than a decade, with countless candidates failing along the way. Researchers are increasingly asking: how can we accelerate this process without compromising safety or...
Neutralizing antibodies have become essential tools across biomedical research, enabling scientists to block receptor–ligand interactions, dissect signaling pathways, and study pathogen entry mechanisms with increasing precision. As research questions grow more specialized, the need for rigorously validated antibody reagents—both broad‑spectrum and highly...
The success of Chimeric Antigen Receptor (CAR) T-cell technology in targeting hematologic malignancies has established a robust blueprint for synthetic immunology. However, for researchers in the fields of molecular biology and cellular engineering, the current frontier lies in the repurposing of this modular platform for non-malignant indications. By decoupling the CAR structure from simple...
In recent years, artificial T‑cell stimulation systems have quietly become essential tools in immunology labs. Not because they are flashy or conceptually new, but because the questions researchers are asking about T‑cell biology have changed. While achieving robust activation remains a foundational step, the field is increasingly interested in how different modes of stimulation shape...
Neuroscience R&D is in the middle of a recalibration. As programs push deeper into complex neurodegenerative and psychiatric biology, developers are rethinking how early‑stage hypotheses should be tested. Rodent models still anchor the field, but in many pipelines they are increasingly reserved for later-stage validation rather than being the default starting point. Instead, small‑model...
In neuroscience, there's a quiet truth that shapes almost every experiment: the model you choose determines the questions you can answer. When studying complex conditions like Alzheimer's, Parkinson's, ALS, or Huntington's disease, this becomes paramount. These disorders don't follow simple rules—they involve networks of cells, shifting environments, and long-term changes that are hard to...
In the shadow of every viral outbreak lies a deeper challenge: how do we deliver therapeutics precisely, safely, and effectively to the cells that need them most? While vaccine development and antiviral discovery often dominate headlines, the unsung hero of modern virology may well be lipid-based drug delivery systems. These microscopic carriers—liposomes, lipid nanoparticles (LNPs), and...
When immune checkpoint antibodies first entered the clinic a decade ago, they were hailed as a revolution. Drugs targeting PD‑1 and CTLA‑4 rewrote the rules of oncology, offering durable responses in cancers once considered untreatable. Today, the story is less about discovery and more about refinement: how to manufacture these complex molecules at scale, how to test them in ever more realistic...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek
